Literature DB >> 26585244

Combination therapy including CpG oligodeoxynucleotides and entecavir induces early viral response and enhanced inhibition of viral replication in a woodchuck model of chronic hepadnaviral infection.

Zhongji Meng1, Xiaoyong Zhang2, Rongjuan Pei2, Ejuan Zhang2, Thekla Kemper2, Jörg Vollmer3, Heather L Davis4, Dieter Glebe5, Wolfram Gerlich5, Michael Roggendorf2, Mengji Lu6.   

Abstract

CpG oligodeoxynucleotides (ODNs) stimulate immune cells via TLR9 and are potentially useful immunomodulators for the treatment of chronic viral infections. In the present study, different classes of CpGs were tested for their capacities for innate immune activation and antiviral activities in the woodchuck model. A class P CpG ODN was found to stimulate interferon (IFN) production in woodchuck peripheral blood mononuclear cells (PBMCs) in vitro, and following subcutaneous administration in vivo, it was observed to induce IFN and MxA expression in woodchuck PBMCs. Combination treatment with CpG ODN and entecavir (ETV) led to effective suppression of the woodchuck hepatitis virus (WHV) load in the woodchucks, with early viral responses and inhibition of replication. The woodchuck hepatitis surface antigen (WHsAg) serum concentrations were strongly decreased by CpG and ETV together but not by either agent alone, indicating synergistic effects. However, viral control post-treatment was still transient, similar to that observed with ETV alone. Significantly elevated levels of serum aspartate aminotransferase (AST) but not of alanine aminotransferase (ALT) in some of the woodchucks receiving CpG ODN were noted, but these increases were resolved before the completion of treatment and were not associated with an elevated serum bilirubin level or coagulation disorders, suggesting the absence of a significant safety concern.
Copyright © 2015. Published by Elsevier B.V.

Entities:  

Keywords:  CpG oligodeoxynucleotides; Hepatitis B virus; Immunotherapy; Toll-like receptor; Woodchuck hepatitis virus

Mesh:

Substances:

Year:  2015        PMID: 26585244     DOI: 10.1016/j.antiviral.2015.11.001

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  18 in total

1.  Activity of nucleic acid polymers in rodent models of HBV infection.

Authors:  Katrin Schöneweis; Neil Motter; Pia L Roppert; Mengji Lu; Baoju Wang; Ingo Roehl; Dieter Glebe; Dongliang Yang; John D Morrey; Michael Roggendorf; Andrew Vaillant
Journal:  Antiviral Res       Date:  2017-11-08       Impact factor: 5.970

2.  Interaction between Toll-Like Receptor 9-CpG Oligodeoxynucleotides and Hepatitis B Virus Virions Leads to Entry Inhibition in Hepatocytes and Reduction of Alpha Interferon Production by Plasmacytoid Dendritic Cells.

Authors:  Ludovic Aillot; Marc Bonnin; Malika Ait-Goughoulte; Nathalie Bendriss-Vermare; Sarah Maadadi; Laura Dimier; Miroslava Subic; Caroline Scholtes; Isabel Najera; Fabien Zoulim; Julie Lucifora; David Durantel
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

Review 3.  Modulators of innate immunity as novel therapeutics for treatment of chronic hepatitis B.

Authors:  Aleksei Suslov; Stefan Wieland; Stephan Menne
Journal:  Curr Opin Virol       Date:  2018-02-20       Impact factor: 7.090

4.  Intramuscular primary immunization by nucleic acid vaccine pcDNA/Gpd-IL-2 and enhanced immunization with mucosal adjuvant CpG-ODN and Gpd-IL-2 recombinant protein effectively induced strong mucosal immune responses and immune protective effects against Treponema pallidum skin infection.

Authors:  Xiaohong Zhang; Tie Zhao; Tiebing Zeng; Ning Wu; Yongjian Xiao; Shuangquan Liu; Jian Yu; Chuanhao Jiang; Lin Gan; Meixia Deng; Xi Luo; Feijun Zhao
Journal:  Exp Ther Med       Date:  2018-01-04       Impact factor: 2.447

Review 5.  Innate immunity and HBV persistence.

Authors:  Carolina Chiale; Anthony M Marchese; Michael D Robek
Journal:  Curr Opin Virol       Date:  2021-05-13       Impact factor: 7.121

6.  The IL-1R/TLR signaling pathway is essential for efficient CD8+ T-cell responses against hepatitis B virus in the hydrodynamic injection mouse model.

Authors:  Zhiyong Ma; Jia Liu; Weimin Wu; Ejuan Zhang; Xiaoyong Zhang; Qian Li; Gennadiy Zelinskyy; Jan Buer; Ulf Dittmer; Carsten J Kirschning; Mengji Lu
Journal:  Cell Mol Immunol       Date:  2017-07-31       Impact factor: 11.530

7.  Safety and efficacy of anti-PD-L1 therapy in the woodchuck model of HBV infection.

Authors:  Scott Balsitis; Volodymyr Gali; Pamela J Mason; Susan Chaniewski; Steven M Levine; Michael J Wichroski; Michael Feulner; Yunling Song; Karen Granaldi; James K Loy; Chris M Thompson; Jacob A Lesniak; Catherine Brockus; Narendra Kishnani; Stephan Menne; Mark I Cockett; Renuka Iyer; Stephen W Mason; Daniel J Tenney
Journal:  PLoS One       Date:  2018-02-14       Impact factor: 3.240

Review 8.  Interplay between the Hepatitis B Virus and Innate Immunity: From an Understanding to the Development of Therapeutic Concepts.

Authors:  Suzanne Faure-Dupuy; Julie Lucifora; David Durantel
Journal:  Viruses       Date:  2017-04-28       Impact factor: 5.048

Review 9.  Interaction between Hepatitis B Virus and Toll-Like Receptors: Current Status and Potential Therapeutic Use for Chronic Hepatitis B.

Authors:  Zhiyong Ma; Qian Cao; Yong Xiong; Ejuan Zhang; Mengji Lu
Journal:  Vaccines (Basel)       Date:  2018-01-16

10.  Direct antiviral properties of TLR ligands against HBV replication in immune-competent hepatocytes.

Authors:  Julie Lucifora; Marc Bonnin; Ludovic Aillot; Floriane Fusil; Sarah Maadadi; Laura Dimier; Maud Michelet; Océane Floriot; Anaïs Ollivier; Michel Rivoire; Malika Ait-Goughoulte; Stéphane Daffis; Simon P Fletcher; Anna Salvetti; François-Loïc Cosset; Fabien Zoulim; David Durantel
Journal:  Sci Rep       Date:  2018-03-29       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.